Hui Liu

Hui Liu

Auto-generated profile, based on publicly available information

Hui Liu

Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Hepatobiliary Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ZDZi-Niu Ding
Zi-Niu Ding
GMGuang-Xiao Meng
Guang-Xiao Meng
JXJun-Shuai Xue
Jun-Shuai Xue
LYLun-Jie Yan
Lun-Jie Yan
HLHui Liu
Hui Liu
TLTao Li
Tao Li

24 April 2017 in Oncotarget
Verified
Journal Article
Open access
YCYangqin Chen
Yangqin Chen
CFChunlei Fan
Chunlei Fan
YCYu-Han Chen
Yu-Han Chen
HLHui Liu
Hui Liu
SWShanshan Wang
Shanshan Wang
HDHuiguo Ding
Huiguo Ding
Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study

1 February 2022 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
KZKe Zhang
Ke Zhang
KHKangkang Han
Kangkang Han
HLHui Liu
Hui Liu
CZChun-yan Zheng
Chun-yan Zheng
Purpose: Increasing evidence has shown that the immune response interacts with the chronic inflammatory response and gives rise to the occurrence and development of COPD. Complement component 1q (C1q), as a subcomponent of the C1 complex, could be involved in innate and adaptive immunity. Our study aimed to investigate the relationship between C1q and the clinical characteristics of COPD subjects. Patients and Methods: Serum C1q levels were measured in 203 COPD subjects and 191 non-COPD controls. Correlations between C1q and the characteristics of COPD were analyzed using Spearman’s rho. Receiver operating curve (ROC) analysis was used to evaluate the threshold value in differentiating disease status. All 203 COPD subjects were followed up for 1 year for future acute exacerbations. Results: There were significant reductions in serum C1q levels in COPD subjects compared to non-COPD controls. Moreover, serum C1q levels were obviously positively correlated with the FEV1/FVC ratio and predicted FEV1% but had a weakly negative correlation with the %LAA-950 and the percentage of neutrophils in peripheral blood. Using a cutoff value of 137.150 mg/l as the boundary in ROC analysis, the sensitivity and specificity were 65.9% and 76.0%, respectively. The 1-year follow-up results showed that C1q levels less than 137.150 mg/l were negatively related to the time to the next severe exacerbation and the time to death. Conclusion: Circulating C1q levels may be a novel biomarker not only related to the pulmonary function of COPD but also having great potential to predict the risk of COPD deterioration in the future. However, further prospective trials are needed to clarify the influences of C1q on the pathogenesis of COPD.

21 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
DWDongxu Wang
Dongxu Wang
HLHui Liu
Hui Liu
JTJin-Cheng Tian
Jin-Cheng Tian
DZDao-Lin Zhang
Dao-Lin Zhang
HLHui Liu
Hui Liu
TLTao Li
Tao Li
The landscape of current tumor treatment has been revolutionized by the advent of immunotherapy based on PD-1/PD-L1 inhibitors. Leveraging its capacity to mobilize systemic antitumor immunity, which is primarily mediated by T cells, there is growing exploration and expansion of its potential value in various stages of clinical tumor treatment. Neoadjuvant immunotherapy induces a robust immune response against tumors prior to surgery, effectively facilitating tumor volume reduction, early eradication or suppression of tumor cell activity, and control of potential metastatic spread, to improve curative surgical resection rates, and prevent tumor recurrence. This review delineates the theoretical basis of neoadjuvant immunotherapy from preclinical research evidence, discusses specific challenges in clinical application, and provides a comprehensive overview of clinical research progress in neoadjuvant immunotherapy for gastrointestinal tumors. These findings suggest that neoadjuvant immunotherapy has the potential to ameliorate immunosuppressive states and enhance cytotoxic T cell function while preserving lymphatic drainage in the preoperative period. However, further investigations are needed on specific treatment regimens, suitable patient populations, and measurable endpoints. Despite numerous studies demonstrating the promising efficacy and manageable adverse events of neoadjuvant immunotherapy in gastrointestinal tumors, the availability of high-quality randomized controlled trials is limited, which highlights the necessity for further research.

30 April 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
QCQi‐Hang Cao
Qi‐Hang Cao
HLHui Liu
Hui Liu
LYLun‐Jie Yan
Lun‐Jie Yan
HWHan‐Chao Wang
Han‐Chao Wang
ZDZi‐Niu Ding
Zi‐Niu Ding
TLTao Li
Tao Li

13 December 2023 in Hepatology
Verified
Journal Article
Closed access
HLHui Liu
Hui Liu
HLHan Li
Han Li
DWDongxu Wang
Dongxu Wang
TLTao Li
Tao Li
An abstract is unavailable. This article is available as a PDF only.